A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Trametinib (Primary) ; Carboplatin; Paclitaxel; Ropidoxuridine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 07 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.